Tests CAR-T cells targeting CD33 and CD123 in acute myeloid leukemia
Tests CAR-T cells given in sequence in people with returning or treatment-resistant acute myeloid leukemia.
Plain-language title generated from the registry record
Registry title: Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with acute myeloid leukemia whose leukemia cells carry CD33, CD123 or CLL-1. They get CAR-T cell treatment aimed at CD33 and CD123.
- Age
- The record gives two different lower limits: older than 6 months, and a minimum age of 6 years. The maximum age is 90 years.
- Sex
- All sexes can join.
- Disease stage
- Acute myeloid leukemia that is refractory or relapsed (title). Good general condition (Karnofsky score higher than 80) and life expectancy of more than 3 months. Heart, lung, liver, kidney and bone marrow function must meet set limits, including hemoglobin of 80 g/L or more.
- Earlier treatment
- No steroid medicine taken by mouth or injection (systemic glucocorticoid) within one week before entering the trial.
- Biomarker or test result
- Leukemia cells must show CLL-1, CD123 and/or CD33, confirmed by staining or flow cytometry.
Main reasons for not taking part
- Severe illness that does not allow following the trial plan
- Active infection that is not controlled by treatment
- Known HIV, hepatitis B or hepatitis C infection
- Pregnant or nursing women
- Systemic glucocorticoid use within one week before the trial
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 90 years old?
Source: NCT06420063, who can take part
Where in China
- District One HospitalBeijing, ChinaContact: SAMI XI, drTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Essen Biotech
- Trial code
- NCT06420063
- Record updated
- 12 November 2024
- Original description
This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD33 or CD123 or both sequentially in the treatment of Acute Myelocytic Leukemia.Read full original descriptionShow less
Sequential CAR-T Cell Infusion Targeting CD33 and CD123 for Refractory/Relapsed Acute Myeloid Leukaemia
This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD33 or CD123 or both sequentially in the treatment of Acute Myelocytic Leukemia.
Inclusion: Subjects with acute myeloid leukemia who voluntarily signed informed consent and met the following criteria:; Age older than 6 months; Confirmed expression of CLL-1, CD123 and/or CD33 in blast AML by immuno-histochemical staining or flow cytometry; Karnofsky performance status (KPS) score is higher than 80 and life expectancy > 3 months; Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: cardiac ejection fraction ≥ 50%, oxygen saturation ≥ 90%, creatinine ≤ 2.5 × upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal, total bilirubin ≤ 2.0mg/dL; Hgb≥80g/L; No cell separation contraindications; Abilities to understand and the willingness to provide written informed consent.
Exclusion: Use of glucocorticoid for systemic therapy within one week prior to entering the trial; Severe illness or medical condition, which would not permit the patient to be managed according to the protocol, including active uncontrolled infection; Active bacterial, fungal or viral infection not controlled by adequate treatment; Known HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; Pregnant or nursing women may not participate; Patients, in the opinion of investigators, may not be able to comply with the study.